Nishino Ichizo, Noguchi Satoru, Murayama Kumiko, Ohkuma Aya, Kasahata Naoki, Malicdan May Christine V, Hayashi Yukiko K, Nonaka Ikuya
Department of Neuromuscular Research, National Institute of Neuroscience, National Center of Neurology and Psychiatry (NCNP).
Rinsho Shinkeigaku. 2005 Nov;45(11):943-5.
Distal myopathy with rimmed vacuoles (DMRV) and hereditary inclusion body myopathy (HIBM) are genetically identical autosomal recessive muscle disorders caused by mutations in the GNE gene. This gene encodes a bifunctional protein with UDP-GlcNAc 2-epimerase and ManNAc kinase activities that catalyze the rate limiting step and the succeeding step, respectively, in the sialic acid biosynthetic pathway. V572L mutation is the most prevalent among Japanese DMRV patients and accounts for about 60% of mutant alleles. Clinical spectrum of DMRV/HIBM seems to be wider than previously thought in terms of both the severity of the disease and the range of affected organs. There are rare asymptomatic homozygotes with missense GNE mutations, indicating the presence of mitigating factors. Surprisingly, more than 10% of the patients had a variety of cardiac abnormalities, suggesting that skeletal muscle may not be the only organ involved. Studies on recombinant GNE demonstrate a loss-of-function nature of the missense mutations identified. Patients' cells show decreased sialylation status which can be recovered by adding GNE metabolites, such as ManNAc and NeuAc. This indicates the possibility of developing a therapy for DMRV/HIBM by giving these metabolites to patients although we have to await the model mice that are currently being produced at several laboratories.
伴有镶边空泡的远端肌病(DMRV)和遗传性包涵体肌病(HIBM)是由GNE基因突变引起的具有相同遗传特征的常染色体隐性肌肉疾病。该基因编码一种具有UDP-GlcNAc 2-表异构酶和甘露糖胺激酶活性的双功能蛋白,分别催化唾液酸生物合成途径中的限速步骤和后续步骤。V572L突变在日本DMRV患者中最为常见,约占突变等位基因的60%。就疾病严重程度和受影响器官范围而言,DMRV/HIBM的临床谱似乎比以前认为的更广。存在罕见的携带错义GNE突变的无症状纯合子,这表明存在减轻因素。令人惊讶的是,超过10%的患者有各种心脏异常,这表明骨骼肌可能不是唯一受累的器官。对重组GNE的研究表明已鉴定出的错义突变具有功能丧失的性质。患者细胞的唾液酸化状态降低,通过添加GNE代谢物(如甘露糖胺和N-乙酰神经氨酸)可以恢复。这表明通过给患者服用这些代谢物来开发DMRV/HIBM治疗方法的可能性,尽管我们必须等待目前几个实验室正在培育的模型小鼠。